Top Industry Leaders in the Tyrosine Hydroxylase Deficiency Market
Latest Tyrosine Hydroxylase Deficiency Companies UpdateBioMarin acquires Ztalmy Therapeutics acquisition strengthens BioMarin's THD portfolio with Ztalmy's promising investigational gene therapy ZT-001, potentially accelerating its development towards clinical trials.Collaboration between Medtronic and Actelion Pharmaceuticals the partnership focuses on developing new treatment options for THD and other dopamine-related disorders by combining Medtronic's deep brain stimulation technology with Actelion's expertise in neurotransmitter modulation.Akcea Therapeutics' phase 2b trial for MIN101 in THD the trial evaluates the safety and efficacy of MIN101, a novel therapy addressing the underlying cause of THD. Early results show promising improvements in motor function and neurotransmitter levels.Gene therapy research for THD companies like Voyager Therapeutics and GeneSight Bio are exploring gene therapy approaches to potentially cure THD by fixing the defective TYH gene. Preclinical studies show promising results, and clinical trials are on the horizon.List of Tyrosine Hydroxylase Deficiency Key Companies in the Market
- Fujifilm Holdings (Japan)
- GE Healthcare (U.S.)
- Siemens Healthcare (U.S.)
- Philips Healthcare (U.S.)
- Shimadzu Corporation (Japan)
- GeneDx (U.S)
- PGxHealth LLC (U.S)
- Abbott (U.S)
- GE Healthcare (U.K)
- Medtronic (U.S.)
- Pfizer, Inc (U.S)
- Boston Scientific Corporation (U.S.)
- GlaxoSmithKline (U.K)
- Eli Lilly and Company (U.S.)
- Taj Pharmaceuticals Ltd (India)
